Stockreport

FDA Accepts Application for Genentech's Gazyva for the Treatment of the Most Common Form of Lupus [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF If approved, Gazyva would be the first anti-CD20 therapy to directly target B cells in SLE, potentially becoming the new standard of care for this condition SLE is a [Read more]